Rituxan (rituximab)

November 22, 2019November 22, 2019

EU Advisory Committee Favors Approval of Polivy with MabThera and Bendamustine for Advanced DLBCL

News

An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment of ... Read more

October 15, 2019

Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show

News

IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials ... Read more

September 6, 2019

Gazyva-Revlimid Effective for Certain Patients with Relapsed or Refractory Follicular Lymphoma, Trial Suggests

News

A combination of Gazyva (obinutuzumab) and Revlimid (lenalidomide) is effective for some patients with follicular lymphoma who failed prior treatments, including those with early relapses, according to a Phase 2 ... Read more

August 16, 2019August 14, 2019

Finding My ‘Big Lymphoma Family’

Columns, Things That Give Me Hope - a Column by Bob McEachern

Cancer has a way of isolating us. Friends and family can be supportive, but sometimes they don’t understand what you’re going through. I have found that it helps to think ... Read more

April 12, 2019

Age, Obesity, Comorbidities Linked with Severe Fatigue Among Non-Hodgkin’s Lymphoma Survivors

News

While a significant proportion of non-Hodgkin’s lymphoma survivors suffer from severe fatigue, the type of initial treatment and Rituxan (rituxumab) use did not influence this outcome, a new study shows. Instead, ... Read more

April 12, 2019April 11, 2019

Living In-between

Columns, Things That Give Me Hope - a Column by Bob McEachern

I have been a follicular lymphoma patient since 2008. One of the strangest things about this disease is the kind of “in-between-ness” that it can put some patients into. You’re ... Read more

February 27, 2019

FDA Grants Priority Review to Polatuzumab Vedotin Combo for Difficult-to-treat DLBCL

News

The U.S. Food and Drug Administration has granted priority review to Roche‘s polatuzumab vedotin in combination with Rituxan (rituximab) and the chemotherapy bendamustine for the treatment of patients with relapsed or refractory ... Read more

January 3, 2019

Phase 3 Trial Testing Biosimilar to Rituxan, JHL1101, in DLBCL Patients Begins

News

Patient dosing has begun in a Phase 3 trial comparing JHL Biotech‘s proposed biosimilar of rituximab JHL1101 to the original medicine, Rituxan (rituximab), in diffuse large B-cell lymphoma (DLBCL), the company announced. The ... Read more

December 4, 2018

Truxima Becomes First Biosimilar to Rituxan Approved in US for Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration has approved Truxima (rituximab-abbs), a biosimilar to Rituxan (rituximab), for three CD20-positive non-Hodgkin’s lymphoma indications, Celltrion and Teva announced. The decision comes less than two months after the FDA’s Oncologic Drugs ... Read more

November 5, 2018

Imbruvica Combo Improves Long-term Survival in CLL/SLL Patients, Updated Phase 3 Results Show

News

Combining AbbVie’s Imbruvica (ibrutinib) with Treanda (bendamustine) and Rituxan (rituximab) improves long-term survival outcomes in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer reappeared or ... Read more